Tharimmune, Inc.

Last year saw just 22 biopharma initial public offerings in the US, down markedly from the record-breaking 107 first-time offerings in 2021, but also well below the prior record set in 2020 and the mo

To say that 2022 has gotten off to a rough start for investors that back biopharmaceutical companies would be an understatement. The Nasdaq Biotechnology Index (NBI) is down 14.3% year-to-date and the

Merging with a special purpose acquisition corporation (SPAC) can be an attractive alternative to an initial public offering for biopharmaceutical companies looking to go public, but SPACs have begun